GTX-102
GTX-102-CL301
Phase 3 small_molecule active
Quick answer
GTX-102 for Angelman Syndrome is a Phase 3 program (small_molecule) at Ultragenyx Pharmaceutical with 4 ClinicalTrials.gov record(s).
Program details
- Company
- Ultragenyx Pharmaceutical
- Indication
- Angelman Syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active